Meeting
2022 ASCO Annual Meeting
WDR49 mutation as a novel predictive biomarker in patients with non–small cell lung cancer with immune checkpoint inhibitors.
Authors
Zhihui Shi
The Second Xiangya Hospital of Central South University, Changsha, China
Zhihui Shi , Yaqin Liu , Lele Zhao , Lin Chen , Qidong Yang , Mingzhe Xiao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2615)
DOI
10.1200/JCO.2022.40.16_suppl.2615
Abstract #
2615
Poster Bd #
270
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Integrative molecular analysis of metastatic Merkel cell carcinoma to identify predictive biomarkers of response to avelumab.
First Author: Sara Georges
Poster
2024 ASCO Annual Meeting
Genomic characteristics of exceptional responders to treatment with PD-1 inhibitors in refractory/metastatic head and neck squamous cell carcinoma.
First Author: Mark Chang
Poster
2023 ASCO Annual Meeting
ARID1A deficiency in triple-negative breast cancer induces adaptive immune resistance and sensitivity to immune checkpoint inhibitors.
First Author: Margaret Chen
Poster
2023 ASCO Genitourinary Cancers Symposium
Pembrolizumab (Pem) in metastatic castration-resistant prostate cancer (mCRPC): Experience from a comprehensive cancer center.
First Author: Arya Mariam Roy